Transforming preclinical assessment to meet clinical relevance with advanced models
- Resource Type
- Authors
- Estelle Marrer-Berger; Thierry Lavé; Thomas Singer; Adrian Roth; Sven Kronenberg; Ekaterina Breous-Nystrom
- Source
- Current Opinion in Toxicology. :39-45
- Subject
- 0301 basic medicine
Clinical trial
03 medical and health sciences
030104 developmental biology
Risk analysis (engineering)
business.industry
Medicine
Clinical significance
010501 environmental sciences
Toxicology
business
01 natural sciences
0105 earth and related environmental sciences
- Language
- ISSN
- 2468-2020
The advances in the immunotherapy field in the last decade have enabled efficient treatment of previously intractable cancers. These advances have also exposed the limitations of commonly used animal models for safety prediction of such drugs. In fact, 90% biological immunotherapies entering clinical trials fail because of low efficacy and/or unmanageable toxicity despite having undergone rigorous preclinical safety assessment. This low predictability is due to challenges related to the poor conservation of key immune-biological aspects between man and standard preclinical safety workhorses. To void this gap, new models are urgently needed. Here, we discuss the growing area of advanced human physiological in vitro and in silico models and propose future directions needed to enable more accurate and faster prediction of drug responses.